Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
News|Articles|March 25, 2026
Promise, Pitfalls, and Progress of Price Transparency in US Health Care: John Barkett
Author(s)Pearl Steinzor
Fact checked by: Julia Bonavitacola
Making health care prices public was supposed to cut costs. The reality is more complicated.
Advertisement
Advertisement
Price transparency was sold as one of health care’s simple fixes. The aim was to show patients and employers what insurers actually pay for their care, allowing market forces to do the rest.
Related to this article
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
Advertisement
Advertisement